Selective c-Myc Inhibitors Targeting Max Leucine Zipper
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current c-Myc inhibitors lack selectivity, leading to severe side effects due to their non-specific action on c-Myc and related transcription factors, making it challenging to develop effective cancer therapies without toxicity issues.
Innovation Solution
Development of novel compounds with specific structures that inhibit c-Myc/Max/DNA complex formation, offering high selectivity and minimizing side effects by targeting the c-Myc/Max heterodimer directly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If indirect c-Myc inhibitors are used to regulate c-Myc function, then c-Myc activity can be modulated, but selectivity is reduced and severe side effects occur
Solution Approach 1:
The patent uses the Max protein as an intermediary to achieve selective inhibition. The compounds do not directly bind to c-Myc but rather to Max, which is essential for c-Myc/Max heterodimer formation. This intermediary approach allows selective disruption of c-Myc function while sparing other transcription factors that do not require Max for their activity, thereby reducing off-target effects and side effects
Solution Approach 2:
The invention targets a specific local feature of the c-Myc/Max interaction - the leucine zipper motif interface - rather than attempting to inhibit c-Myc globally. By designing compounds that specifically bind to the Max leucine zipper region, the patent achieves localized inhibition of c-Myc/Max heterodimerization while maintaining selectivity and avoiding widespread disruption of other cellular processes
2Reliability
If substances binding to the leucine zipper motif are used to inhibit Myc/Max heterodimer formation, then heterodimer formation is inhibited, but selectivity is low and side effects are caused
Solution Approach 1:
The patent applies local quality by targeting the specific leucine zipper motif of Max protein, which is a unique structural feature required for Myc/Max heterodimer formation. The compounds are designed to bind specifically to this localized region, disrupting the heterodimer interface without affecting other transcription factor complexes that use different binding mechanisms
Solution Approach 2:
The invention changes the binding parameters by developing compounds with specific molecular characteristics that preferentially bind to the Max leucine zipper motif over other protein interfaces. By optimizing parameters such as molecular size, hydrophobicity, and specific functional group placement, the patent achieves high selectivity for Max while maintaining potent inhibition of heterodimer formation
3Reliability
If inhibitors with broad activity against c-Myc and related transcription factors are developed, then c-Myc function is inhibited, but selectivity is reduced leading to toxicity
Solution Approach 1:
The patent employs Max protein as a selective intermediary target. Since Max is specifically required for c-Myc oncogenic activity but not for the function of other transcription factors like Fos/Jun, inhibiting Max selectively disrupts c-Myc signaling while preserving other transcriptional programs, thereby achieving c-Myc inhibition without the toxicity associated with broad-spectrum inhibitors
Solution Approach 2:
The invention extracts the Max component from the c-Myc/Max heterodimer complex as a separate therapeutic target. By focusing specifically on Max inhibition rather than attempting to inhibit all transcription factors, the patent isolates the essential element required for c-Myc oncogenic function, achieving selective toxicity against cancer cells driven by c-Myc while sparing normal cells
Data Source
AI summary
Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.